Femasys (FEMY)
(Delayed Data from NSDQ)
$1.30 USD
+0.08 (6.56%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $1.30 0.00 (0.00%) 5:32 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.30 USD
+0.08 (6.56%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $1.30 0.00 (0.00%) 5:32 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device
by Zacks Equity Research
FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI
by Zacks Equity Research
FEMY's eco-friendly FemVue MINI receives CE Mark and Health Canada approval, advancing sustainable fallopian tube assessment technology in Europe and Canada.
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Femasys (FEMY) delivered earnings and revenue surprises of -16.67% and 55.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 16.67% and 71.27%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 65.41% and 137.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Femasys (FEMY) delivered earnings and revenue surprises of 22.73% and 9.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
IGM Biosciences (IGMS) delivered earnings and revenue surprises of 1.19% and 30.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 0% and 7.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Femasys (FEMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Femasys' (FEMY) revenues in third-quarter 2023 are expected to have been driven by the higher international sales of its marketed products. Pipeline updates are expected over the earnings call.
Bears are Losing Control Over Femasys Inc. (FEMY), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Femasys Inc. (FEMY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Femasys Inc. (FEMY) delivered earnings and revenue surprises of -8.70% and 13.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 336.84% and 93.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Femasys Inc. (FEMY) delivered earnings and revenue surprises of 15.38% and 1%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -16.46% and 12.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?